Medtech Dive Outlook for 2023

After a few bumpy years marked by the COVID-19 pandemic, supply chain challenges and global inflation, medical device companies are looking for signs of stability going into 2023.

Although the pandemic and hospital staffing shortages linger, medtech companies expect procedure volumes to improve.

Mergers and acquisitions are expected to pick up again in 2023,after a slowdown last year. Larger firms flush with cash after spinning out slower-growing business segments, and a slow IPO market are expected to fuel the trend.

Companies are also watching major regulatory changes in the European Union, as regulators discuss moving back the formal implementation of MDR to 2027 or 2028, which would give medical device companies more time to come into compliance. In the U.S., the Food and Drug Administration is wrangling with how to best regulate emerging technologies, such as machine learning software in medical devices.

Finally, diabetes companies including Dexcom, Tandem and Abbott are preparing for major product launches this year, as they push for broader coverage in the U.S. and overseas.

MedTech Dive’s outlook series explores key trends and topics fort he sector in 2023, as the industry manages through another pandemic year while grappling with a potential recession.

Request Free!

After a few bumpy years marked by the COVID-19 pandemic, supply chain challenges and global inflation, medical device companies are looking for signs of stability going into 2023.

Although the pandemic and hospital staffing shortages linger, medtech companies expect procedure volumes to improve.

Mergers and acquisitions are expected to pick up again in 2023,after a slowdown last year. Larger firms flush with cash after spinning out slower-growing business segments, and a slow IPO market are expected to fuel the trend.

Companies are also watching major regulatory changes in the European Union, as regulators discuss moving back the formal implementation of MDR to 2027 or 2028, which would give medical device companies more time to come into compliance. In the U.S., the Food and Drug Administration is wrangling with how to best regulate emerging technologies, such as machine learning software in medical devices.

Finally, diabetes companies including Dexcom, Tandem and Abbott are preparing for major product launches this year, as they push for broader coverage in the U.S. and overseas.

MedTech Dive’s outlook series explores key trends and topics fort he sector in 2023, as the industry manages through another pandemic year while grappling with a potential recession.

Request Free!